ZipLine Medical Secures $12 Million in New Financing

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.


ZipLine Medical, Inc. announced today that they have completed a $12 million Series E round of financing.  (Proceeds from the financing will be used to continue worldwide commercialization activities for its Zip® Surgical Skin Closure products, as well as development of advanced tools to reduce post-discharge costs in a bundled care environment).

HighCape Partners, a growth equity fund based in New York which invests broadly across the healthcare sector, led the financing.   The financing includes participation from existing investor MVM Life Science Partners LLP.

Dean Tozer, Operating Partner of HighCape Partners reported, “ZipLine Medical has introduced a revolution in surgery – advanced wound closure that addresses inherent limitations with traditional, antiquated methods. The ZipLine team is developing and marketing disruptive products that minimize risk, improve clinical outcomes and address the constant pursuit of cost-effective healthcare.” (As part of the financing, Tozer has joined the ZipLine Medical Board of Directors).

Founder of HighCape Partners, Matt Zuga added, “We are excited to help propel the company to the next level of growth and commercial success.”

“This financing will allow us to further expand our global business, as well as introduce new products that improve upon the standard of care while driving down healthcare costs,” said John Tighe, President and Chief Executive Officer of ZipLine Medical.

“We are pleased to have HighCape Partners’ support for ZipLine Medical.  Their experience in the wound care market will be invaluable for the commercial roll-out of the company’s novel product suite,” added Bali Muralidhar, Partner at MVM Life Science Partners.



Related Articles